CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response S Chatterjee, A Daenthanasanmak, P Chakraborty, MW Wyatt, P Dhar, ... Cell metabolism 27 (1), 85-100. e8, 2018 | 231 | 2018 |
Pro-survival lipid sphingosine-1-phosphate metabolically programs T cells to limit anti-tumor activity P Chakraborty, SG Vaena, K Thyagarajan, S Chatterjee, A Al-Khami, ... Cell reports 28 (7), 1879-1893. e7, 2019 | 71 | 2019 |
The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer A Ganguly, P Chakraborty, K Banerjee, SK Choudhuri European Journal of Pharmaceutical Sciences 51, 96-109, 2014 | 69 | 2014 |
Synthesis, spectroscopic characterization, X-ray powder structure analysis, DFT study and in vitro anticancer activity of N-(2-methoxyphenyl)-3-methoxysalicylaldimine B Chattopadhyay, S Basu, P Chakraborty, SK Choudhuri, AK Mukherjee, ... Journal of Molecular Structure 932 (1-3), 90-96, 2009 | 69 | 2009 |
Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice A Daenthanasanmak, S Iamsawat, P Chakraborty, HD Nguyen, D Bastian, ... Blood, The Journal of the American Society of Hematology 133 (3), 266-279, 2019 | 67 | 2019 |
A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells S Chatterjee, A Mookerjee, J Mookerjee Basu, P Chakraborty, A Ganguly, ... PLoS One 4 (9), e7048, 2009 | 58 | 2009 |
Targeting PIM kinase with PD1 inhibition improves immunotherapeutic antitumor T-cell response S Chatterjee, P Chakraborty, A Daenthanasanmak, S Iamsawat, ... Clinical cancer research 25 (3), 1036-1049, 2019 | 51 | 2019 |
Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naive CD4+ T cells S Chatterjee, S Das, P Chakraborty, A Manna, M Chatterjee, ... Immunobiology 218 (5), 718-724, 2013 | 51 | 2013 |
Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate A Ganguly, S Basu, P Chakraborty, S Chatterjee, A Sarkar, M Chatterjee, ... PLoS One 5 (6), e11253, 2010 | 51 | 2010 |
Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response S Vaena, P Chakraborty, HG Lee, AH Janneh, MF Kassir, G Beeson, ... Cell reports 35 (5), 2021 | 45 | 2021 |
Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate P Chakraborty, S Chatterjee, A Ganguly, P Saha, A Adhikary, T Das, ... Journal of leukocyte biology 91 (4), 609-619, 2012 | 44 | 2012 |
Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative A Ganguly, K Banerjee, P Chakraborty, S Das, A Sarkar, A Hazra, ... Biomedicine & Pharmacotherapy 65 (6), 387-394, 2011 | 40 | 2011 |
Lack of p53 augments antitumor functions in cytolytic T cells A Banerjee, K Thyagarajan, S Chatterjee, P Chakraborty, P Kesarwani, ... Cancer research 76 (18), 5229-5240, 2016 | 36 | 2016 |
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells P Chakraborty, S Chatterjee, P Kesarwani, K Thyagarajan, S Iamsawat, ... Journal of Biological Chemistry 294 (23), 9198-9212, 2019 | 35 | 2019 |
Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis A Ganguly, S Basu, K Banerjee, P Chakraborty, A Sarkar, M Chatterjee, ... Molecular BioSystems 7 (5), 1701-1712, 2011 | 35 | 2011 |
Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. OB Janneh AH, Kassir MF, Dwyer CJ, Chakraborty P, Pierce JS, Flume PA, Li H ... Scientific Reports 11 (1), 2021 | 29 | 2021 |
HuR as a molecular target for cancer therapeutics and immune-related disorders M Majumder, P Chakraborty, S Mohan, S Mehrotra, V Palanisamy Advanced drug delivery reviews 188, 114442, 2022 | 28 | 2022 |
ROS and RNS induced apoptosis through p53 and iNOS mediated pathway by a dibasic hydroxamic acid molecule in leukemia cells K Banerjee, A Ganguly, P Chakraborty, A Sarkar, S Singh, M Chatterjee, ... European Journal of Pharmaceutical Sciences 52, 146-164, 2014 | 25 | 2014 |
Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff’s base to overcome MDR in cancer S Basu, A Ganguly, P Chakraborty, R Sen, K Banerjee, M Chatterjee, ... Biochimie 94 (1), 166-183, 2012 | 25 | 2012 |
An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone) glycinate to overcome multidrug resistance in cancer RD Ghosh, S Das, A Ganguly, K Banerjee, P Chakraborty, A Sarkar, ... Dalton Transactions 40 (41), 10873-10884, 2011 | 25 | 2011 |